Products TAK-659
TAK-659 Phase 2 Terminated 💤 Quiet Interest: 17/100
Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Oct 10, 2017 → Dec 17, 2019
About TAK-659 TAK-659 is a phase 2 stage product being developed by Calithera Biosciences for Diffuse Large B-cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03123393. Target conditions include Diffuse Large B-cell Lymphoma.
What happened to similar drugs? 1 of 20 similar drugs in Diffuse Large B-cell Lymphoma were approved
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT03359733 Phase 1 Withdrawn Feb 28, 2018 Aug 20, 2019 Lymphoma, Malignant NCT03123393 Phase 2 Terminated Oct 10, 2017 Dec 17, 2019 Diffuse Large B-cell Lymphoma NCT03238651 Phase 1 Terminated Aug 1, 2017 Aug 17, 2020 Lymphoma, Non-Hodgkin NCT02323113 Phase 1/2 Terminated Mar 9, 2015 Aug 15, 2018 Acute Myelogenous Leukemia NCT02000934 Phase 1 Completed Dec 31, 2013 Jun 29, 2021 Advanced Solid Tumor and Lymphoma Malignancies
Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2